152 related articles for article (PubMed ID: 28838714)
21. Heterogeneity in Malignant Pleural Mesothelioma.
Oehl K; Vrugt B; Opitz I; Meerang M
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29848954
[TBL] [Abstract][Full Text] [Related]
22. Hypoxia Inducible Factor-1α Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
Shukuya T; Oyanagi J; Serizawa M; Watanabe M; Yamamoto N; Koh Y
Anticancer Res; 2020 Apr; 40(4):1867-1874. PubMed ID: 32234874
[TBL] [Abstract][Full Text] [Related]
23. An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.
Sato M; Matsui A; Shimoyama Y; Omote N; Morise M; Hase T; Tanaka I; Suzuki K; Hasegawa Y
Intern Med; 2018 Dec; 57(23):3429-3432. PubMed ID: 30101911
[TBL] [Abstract][Full Text] [Related]
24. Improvement of malignant pleural mesothelioma immunotherapy by epigenetic modulators.
Hamaidia M; Staumont B; Duysinx B; Louis R; Willems L
Curr Top Med Chem; 2016; 16(7):777-87. PubMed ID: 26303419
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
[TBL] [Abstract][Full Text] [Related]
26. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment with an EGFR tyrosine kinase inhibitor Afatinib in a patient with combined small-cell lung Cancer with EGFR mutation.
Tanaka M; Ishii H; Moribuchi H; Naito Y; Matsuo N; Nakamura M; Tokito T; Azuma K; Yamada K; Hoshino T
Invest New Drugs; 2018 Aug; 36(4):715-717. PubMed ID: 29546681
[TBL] [Abstract][Full Text] [Related]
28. A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.
Chen Y; Chen B; Zhu X; Zhong J
Lung Cancer; 2018 Feb; 116():96-98. PubMed ID: 29146159
[No Abstract] [Full Text] [Related]
29. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
30. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
31. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
32. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
[TBL] [Abstract][Full Text] [Related]
33. Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in
Abdallah SM; Hirsh V
Curr Oncol; 2018 Jun; 25(Suppl 1):S9-S17. PubMed ID: 29910643
[TBL] [Abstract][Full Text] [Related]
34. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
[TBL] [Abstract][Full Text] [Related]
35. Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations.
Tanaka I; Morise M; Kodama Y; Matsui A; Ozawa N; Ozone S; Goto D; Miyazawa A; Hase T; Hashimoto N; Sato M; Hasegawa Y
Lung Cancer; 2019 Jan; 127():169-171. PubMed ID: 30477806
[No Abstract] [Full Text] [Related]
36. Afatinib with subsequent surgery in stage III NSCLC with EGFR mutation: Lessons learned from two clinical experiences.
Mazzoni F; Petreni P; Perna M; Scotti V; Bongiolatti S; Livi L; Di Costanzo F; Voltolini L
Tumori; 2018 Dec; 104(6):NP5-NP9. PubMed ID: 29895214
[TBL] [Abstract][Full Text] [Related]
37. Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O; Kaira K; Mouri A; Shiono A; Hashimoto K; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Cancer Chemother Pharmacol; 2019 May; 83(5):817-825. PubMed ID: 30758646
[TBL] [Abstract][Full Text] [Related]
38. Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma.
Jian H; Han Y; Yu Y; Lu S
Anticancer Drugs; 2019 Sep; 30(8):873-878. PubMed ID: 31283542
[TBL] [Abstract][Full Text] [Related]
39. A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.
Ninomiya T; Nogami N; Kozuki T; Harada D; Kubo T; Ohashi K; Kuyama S; Kudo K; Bessho A; Fukamatsu N; Fujimoto N; Aoe K; Shibayama T; Sugimoto K; Takigawa N; Hotta K; Kiura K
Lung Cancer; 2018 Jan; 115():103-108. PubMed ID: 29290249
[TBL] [Abstract][Full Text] [Related]
40. Cyclooxygenase-2, epidermal growth factor receptor, and aromatase signaling in inflammation and mesothelioma.
Nuvoli B; Galati R
Mol Cancer Ther; 2013 Jun; 12(6):844-52. PubMed ID: 23729401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]